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Abstract
Background: Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, or the congenital absence of uterus and vagina, is
the most severe anomaly of the female reproductive tract. It affects 1 in 5,000 females, and is the second most
common cause of primary amenorrhea. The etiology remains unknown in most patients, although four single gene
defects and some repetitive copy number variants (CNVs) have been identified. Translocations in MRKH patients are
very rare, and reported only in three patients previously without breakpoint mapping. We have identified the fourth
MRKH translocation patient and are the first to characterize the breakpoints mapped by molecular methods.
Results: The proband is a 17- year old white female with agenesis of the uterus and vagina who had a peripheral
blood karyotype revealing a de novo balanced translocation 46,XX,t(3;16)(p22.3;p13.3)dn. There were no known related
anomalies present in the proband or her family. No CNVs were found by chromosomal microarray analysis, and no
genes were directly disrupted by the translocation. DNA sequencing of six nearby candidate genes—TRIM71, CNOT10,
ZNF200, OR1F1, ZNF205, and ZNF213—did not reveal any mutations. RT-qPCR of proband lymphoblast RNA for 20
genes near the breakpoints of 3p22.3 and 16p13.3 showed significantly altered expression levels for four genes in the
proband compared to three white female controls, after correction for multiple comparisons. Reduced expression was
seen for CMTM7 and CCR4 on 3p22.3, while increased expression was observed for IL32 and MEFV on 16p13.3.
Conclusion: We have mapped the breakpoints of our t(3;16)(p22.3;p13.3) translocation patient using molecular
methods to within 13.6 kb at 3p22.3 and within 1.9 kb for 16p13.3 and have suggested 10 nearby genes that become
plausible candidate genes for future study.
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Background
Abnormal development of the uterus and vagina affects
7-10 % of women, comprising a significant cause of
impaired reproductive function [1]. Mayer-Rokitansky-
Kuster-Hauser (MRKH) syndrome, also known as con-
genital absence of the uterus and vagina or mullerian
aplasia, is the most severe anomaly of the female repro-
ductive tract in which the uterus and vagina are absent
from birth [1]. MRKH (the name patients prefer) affects
approximately 1 in 5,000 females, and is the second
most common cause of primary amenorrhea [1]. These
women are 46,XX females that lack the vagina and most
of the uterus, although fallopian tubes may be present
[2]. Ovaries are present with normal function, thus pa-
tients undergo spontaneous puberty.
MRKH is commonly classified with regard to the pres-
ence or absence of additional anomalies [2, 3]. Isolated
agenesis of the uterus and vagina occurs in about two-
thirds of MRKH patients, classified as Type I. The
remaining one-third of MRKH patients have one or
more associated anomalies, and are classified as Type II.
More frequent associated anomalies involve the kidneys
with renal agenesis (32 %) and the skeletal system (12 %)
[3]. Less commonly, women with MRKH may also
present with deafness, inguinal hernia, or abnormalities
of the cardiac or nervous systems [3].
While the etiology of MRKH is not well understood, dis-
ease clustering in >67 families clearly indicates a genetic
component [4]. A number of candidate genes including
AMH, AMHR, WT1, WNT7A, CFTR, GALT, HOXA7,
HOXA13, PBX1, HOXA10, RARG, RXRA, CTNNB1, PAX2,
LAMC1, DLGH1, and SHOX have been screened for muta-
tions in small numbers of MRKH patients, but no muta-
tions were found [5–9]. Genomic regions 16p11 and 17q12
most commonly have been found to have copy number
variants (CNVs) identified by chromosomal microarray
analysis implicated in MRKH, but causation is difficult to
prove [10, 11]. It is currently not clear if MRKH is a
genomic disorder or if a single gene or several genes within
these CNVs could be etiologic [5]. Single gene defects have
uncommonly been identified–only a few patients have
WNT4 [12–15], LHX1 [16], HNF1B [17], or TBX6 [18]
gene mutations. The molecular basis for MRKH remains
unknown in the vast majority of patients [5].
Patients with balanced translocations provide a unique
and valuable opportunity to identify genes involved in
human genetic disorders [19]. The derivative chromosome
breakpoint may disrupt or dysregulate genes, suggesting a
genomic region of etiologic candidate genes [20]. This
method has been successful in identifying candidate genes
in other disorders, and may be valuable to elucidating the
molecular mechanisms of MRKH [20]. Only three MRKH
patients with balanced translocations have been reported
in the literature, but fine mapping by molecular methods
has not been performed for any of them [21, 22]. In this
study we present an MRKH patient with a de novo
balanced translocation of 46,XX,t(3;16)(p22.3;p13.3)dn
with the purpose to: 1) identify the molecular breakpoints
of 3p22 and 16p13; 2) propose candidate genes for
MRKH; and 3) compare the proband to other MRKH
patients with balanced translocations presented in the
literature.
Case presentation
The proband is a 17-year-old white female with agenesis
of the uterus and vagina who had a peripheral blood
karyotype revealing a de novo balanced translocation
46,XX,t(3;16)(p22.3;p13.3). She has no associated renal,
skeletal, or hearing anomalies. She has two unaffected
sisters and two brothers (Fig. 1). Both parents and her
unaffected sister II-5 have normal karyotypes, and all
three nieces (III-1, III-2, and III-3) have no known mul-
lerian, renal, or skeletal defects.
Results
Flow sorting of both derivative chromosomes 3 and 16
followed by comparative genomic hybridization (CGH)
showed no deletions or duplications, and the breakpoints
were localized (Fig. 2). The breakpoint of der(3) was nar-
rowed to within 13.6 kb at 3p22.3; and to within 1.9 kb on
16p13.3. In neither derivative chromosome was a gene dir-
ectly disrupted, but nearby genes become candidate genes
for MRKH (Fig. 2).
Six genes near the breakpoints were prioritized as rea-
sonable candidate genes based upon either expression in
appropriate tissues and/or proposed gene function. DNA
sequencing was performed on genomic DNA from 51
MRKH patients for the protein coding exons and splice
junctions for the two closest candidate genes near the
breakpoint at 3p22.3—TRIM71 centromeric and CNOT10
telomeric. In addition, ZNF200, OR1F1, ZNF213, and
ZNF205 at 16p13.3 were sequenced in 27 MRKH patients.
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Fig. 1 The pedigree is shown for the proband with a de novo
t(3;16) translocation
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potentially causative (nonsynonymous missense changes)
variants were identified for any of these six genes.
Since the translocation could disrupt regulatory ele-
ments, we performed RT-qPCR from lymphoblastoid
RNA from the proband for 20 genes near the break-
points to see which ones, if any, had altered expression.
This could provide additional supportive evidence for a
candidate gene(s). Using the CT method [23], four
genes in the proband had significantly different expres-
sion from the mean of three white female controls after
correction for multiple comparisons. These included
two genes on chromosome 3p22.3—CMTM7 with 0.22
fold (78 % reduction) and CCR4 with a 0.64 fold (36 %
reduction) change—and two genes on chromosome
16p13.3—IL32 with 7.3 fold and MEFV with 1.6 fold in-
creases in expression (Fig. 3). The altered expression of
these four genes reached significance by a Z-test with a
P < 0.00001 (P < 0.0025 was considered significant after
Bonferroni correction).
Discussion and conclusions
The etiology of MRKH remains largely unknown [5, 24],
although when families are examined, autosomal domin-
ant or multifactorial/polygenic inheritance seems most
likely [4]. Several potentially causative repetitive CNVs
have been described—most commonly deletions in 17q12
(n > 9) and 16p11 (n >5) [5], but it is not clear if they play
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Fig. 3 Log2 fold-change from RT-qPCR of 20 genes located near the breakpoints of chromosome 3p22.3 and 16p13.3. Statistically significant altered
gene expression (P < 0.00001) is indicated by an asterisk for four genes
Williams et al. Molecular Cytogenetics  (2016) 9:57 Page 3 of 7
even less commonly. To date, four WNT4 [12–15], one
LHX1 [16], one HNF1B [17], and several TBX6 [18] muta-
tions and intragenic CNVs [18] have been characterized,
indicating that many more genes for MRKH remain to be
discovered.
While syndromic families have been reported, they are
few and small in size [4]. Thus their ability to show genetic
segregation among affected family members is very lim-
ited. Most MRKH probands do not have a family history
of other affected individuals. The inability of affected
women to conceive and carry children is a significant bar-
rier to characterizing inheritance patterns and identifying
causative genes. However, when MRKH patients who
underwent surrogacy were surveyed by a questionnaire,
32/53 (60 %) responded and 34 liveborns were delivered.
Half were females, and only one child—a male—had a
middle ear defect and hearing loss (1 of 17 = 5.9 %), con-
sistent with an associated phenotype of MRKH [25]. It is
possible that less severe associated anomalies may not
have been ascertained.
Genomic rearrangements, which include balanced
translocations, occur more frequently than de novo point
mutations, and may directly disrupt a gene, thereby alter-
ing its normal function, or result in a sufficient “position
effect” to alter or impair its regulatory mechanisms. [20]
Candidate genes suggested by this position effect have
facilitated successful identification of causative mutations
in multiple disorders, including PAX6 in aniridia, PITX2
in Reiger syndrome, FOXL2 in blepharophimosis/ptosis-
epicanthus inversus syndrome, SOX9 in campomelic dys-
plasia, SRY in sex reversal, SIX3 in holoprosencephaly, and
WDR11 in hypogonadotropic hypogonadism/Kallmann
syndrome [20, 26]. Balanced translocations in affected
individuals highlight a narrow section of the genome that
is disrupted, and can provided much needed clues to the
etiology of human disease [27].
In MRKH, only several translocations have been reported
in the literature (Table 1). In 1988, Kucheria et al. [21]
reported two unrelated females with MRKH who had
translocations involving chromosomes 12q and 14q
(no further cytogenetic details are provided). In 1999,
Amesse et al. [22] reported an adolescent with MRKH, who
also lacked nipples and breasts (amastia/amelia), with
associated urinary reflux, urinary incontinence, and
megaurethra. In peripheral blood, she had a de novo
46,XX,t(8;13)(q22.1;q32.1). When buttock fibroblasts were
analyzed by karyotype, a 4:1 chromosomal mosaicism was
observed, with the predominant 46,XX,t(8;13)(q22.1;q32.1)
cell line, but also a more complex t(1;12)(q23.1;q24.3),
t(6;6)(q15;p25) translocation. Amesse et al. [22] acknow-
ledge that the patient’s lack of breast and areolar tissue is
uncommon in MRKH, and that the translocation of the
less frequent cell line is of unknown significance. These
two reports were prior to the advent of chromosomal
microarrays, and so the molecular breakpoints were not
analyzed to determine the specific breakpoint. Our pa-
tient is the first MRKH translocation patient, with a
typical clinical presentation, to have the translocation
breakpoints mapped by molecular methods, which
should help narrow down the number of putative
candidate genes.
In the current study, we mapped the molecular
breakpoints in an MRKH female with a de novo
46,XX,t(3;16)(p22.3;p13.3)dn. A chromosomal micro-
array was used to narrow down the breakpoints of both
derivative chromosomes to within 13.6 kb on der(3)
and within 1.9 kb on der(16). No deletions/insertions
were identified, which could have been potential
confounders in this patient. No gene was directly dis-
rupted, but the genes closest on either side of the
breakpoint became prime positional candidate genes.
We did not amplify and clone the breakpoints in this
patient since the breakpoint region is not contained
within a structural gene. TRIM71 (tripartite motif-
containing 71) on the centromeric side of the break-
point (Fig. 2) has been reported to be involved in the
timing of organ formation during development [28],
while CNOT10 on the telomeric side of the breakpoint
is involved in transcription [29]. We did not identify
mutations in our available sample of 51 MRKH patients
in these genes, which suggests they are not a common
etiologic factor in MRKH. However, we cannot exclude
Table 1 Reported translocations in patients with MRKH
Author Case # Translocation De novo Ethnicity Phenotype
Kucheria et al. [21] 1 46,XX,t(12q;14q) ? Not stated MRKH
2 46,XX,t(12q;14q) ? Not stated MRKH; renal agenesis
Amesse et al. [22] 3 46,XXt(8;13)(q22.1;q32.1) in blood;
Mosaic in 4:1 ratio in buttock
fibroblasts for minor cell line
of 46,XX, t(1;12)(q23.1;q24.3),
t(6;6)(q15;p25)
Yes Not stated MRKH; congenital amastia/amelia,u
rinary reflux; urinary incontinence,
megarethra
Williams et al.; Current
case
4 46,XX, t(3;16)(p22.3;p13.3). Yes Caucasian Northern European MRKH
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that genes with mutation frequencies of 1-2 % could
occur. We also performed DNA sequencing for three
genes near the breakpoint on chromosome 16p13.3,
namely OR1F1 on the centromeric side and three zinc
finger genes involved in transcription—ZNF213 and
ZNF205 on the telomeric side and ZNF200 on the
centromeric side of the breakpoint. In 27 unrelated
MRKH patients, no putative mutations were identified.
In addition, RNA was extracted from peripheral lym-
phoblastoid cells from our proband, and 20 genes near the
breakpoints of both derivative chromosomes were sub-
jected to RT-qPCR. Expression was normalized to the
GAPDH reference gene and compared to three white fe-
male controls. Four genes were found to have statistically
altered gene expression after correction for multiple com-
parisons. It is interesting that both genes on chromosome
3p22.3, CMTM7 and CCR4, have reduced expression,
while both genes on 16p13.3, IL32 and MEFV, show
increased expression. It is interesting to speculate whether
the 3p genes regulate the 16p genes or vice versa. This will
have to be determined experimentally in future studies.
Two genes—CMTM7 and IL32—have the most profound
differences, so they are the most plausible involved genes
within the breakpoints.
Through the fine mapping of the breakpoints in this
translocation patient, we have identified six candidate
genes that require future testing based upon the location
and proposed role in mullerian development—TRIM71
and CNOT10 on chromosome 3, and OR1F1, ZNF213,
ZNF200, and ZNF205 on chromosome 16. By RT-qPCR,
we show altered expression of four additional genes—
CMTM7 and CCR4 on chromosome 3, and IL32 and
MEFV on chromosome 16—that become reasonable can-
didate genes. Balanced chromosomal translocations may
exert a position effect on genes within 10 kb or even up to
a megabase away from the breakpoint [20]. However, add-
itional patients will need to be collected and studied to ad-
equately test the hypothesis that these are involved in the
pathogenesis of MRKH. Since deleterious gene mutations
affecting most reproductive disorders usually occur at a
frequency between 1-5 % [30, 31], large cohorts are neces-
sary for sufficient power to identify new causative genes.
To date, balanced translocations from MRKH patients
have not yielded causative genes in the etiology of the syn-
drome, but our more comprehensive molecular analysis of
a t(3;16) translocation pinpoints specific chromosomal re-
gions that will require further study. It is also certainly
possible that causal variants could be localized outside the
structural genes and might be detected by whole genome
sequencing approaches. Nevertheless, the complicated
genetic basis of MRKH remains unsolved, but study of
large cohorts and families by innovative molecular ap-
proaches, appropriate in vitro confirmation of identified
variants, and relevant mouse models will be necessary.
Methods
MRKH Patients
Our 52 patients with MRKH, except the proband with the
t(3;16), were 46,XX females with adult (Tanner 5) breast
development, normal pubic hair, and an absent vagina.
Ultrasound or MRI was performed on some patients re-
vealing hypoplasia or aplasia of the uterus. Associated
anomalies were present in patients as follows: unilateral
renal agenesis (n =7), skeletal anomalies (n = 6), cardiac
defects (n = 3), and hearing loss (n = 5). All patients con-
sented to have blood drawn for molecular analysis and
signed a consent approved by the Human Assurance
Committee of the Medical College of Georgia at Augusta
University. LCL was funded by NIH HD33004 and the
Department of Ob/Gyn at Augusta University, which were
the sole sources of funding.
CGH arrays
For breakpoint mapping, we did array painting essentially
as described previously [32]. Briefly, the EBV-transformed
patient lymphoblastoid cell line was treated with colcemid,
and metaphase chromosomes were then isolated and flow-
sorted. Approximately 6,000 flow-sorted chromosomes
were used directly for amplification with the GenomiPhi
V2 DNA Amplification Kit (GE Healthcare, Piscataway, NJ,
USA) according to the manufacturer’s recommendations.
One microgram of amplified DNA from each derivative
chromosome was labelled via Agilent´s Genomic DNA
Enzymatic Labeling Kit Plus (Agilent). To each labelling
reaction 100 ng of genomic control DNA were added to
ensure proper placement of the grid for subsequent image
analysis. These probes were hybridized to a custom array
for high resolution breakpoint mapping. All hybridizations
were done according to the manufacturer's recommenda-
tions for array CGH experiments (Agilent). Further analysis
and visualization of array painting data was done using the
array CGH software package CGHPRO [33].
Sanger DNA sequencing
DNA sequencing of all protein coding exons and splice
junctions was performed on 51 MRKH patients for 4
exons in TRIM71 (NM_001039111.2) and 19 exons in
CNOT10 (NM_015442.2) at the 3p22.3 breakpoint. In
addition, 27 MRKH patient DNAs were subjected to
Sanger sequencing for the 4 exons of ZNF200
(NM_003454.3), 1 exon of OR1F1 (NM_012360.1), 5
exons of ZNF213 (NM_004220.2), and 6 exons of
ZNF205 (NM_001278158.1) at 16p13.3.
RT-qPCR methods
RNA was extracted from lymphoblastoid cells of the pro-
band with the translocation and three white female con-
trols using the TRI REAGENT (Molecular Research
Center, Inc, Cincinnati, OH) standard protocol. RT-qPCR
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primers were designed with a product size of <155 bp for
20 genes around the chromosome 3 and chromosoms16
breakpoints. These genes included: CMTM6, CMTM7,
CMTM8, DYNC1LI1, CNOT10, TRIM71, CCR4, GLB1,
TMPPE, CRTAP, IL32, ZSCAN10, ZNF205, ZNF213,
OR1F1, ZNF200, MEFV, ZNF263, TIGD7, and ZNF75A.
GAPDH was used as the internal reference control.
The RT reaction was performed using the ABI-High
Capacity cDNA Reverse Transcription Kit [RXN w/o
RNAse Inhibitor] (Thermo Fisher Scientific, Waltham,
MA). 2 μg of RNA were used in the 20 μl reaction with
RT conditions of: 25 °C for 10 min, 37 °C for 120 min,
85 °C for 5 min, 4 °C cooling. The cDNA product was di-
luted 1:5 for the qPCR reaction, which was run on a Roche
LightCycler 96 using the FastStart Essential DNA Green
Master Kit protocol (Roche Diagnostics Corporation,
Indianapolis, IN) with SYBR green. In the 25 μl reaction
volume 2 μl of cDNA was used and each primer con-
centration was 25 pmol. GAPDH and each of the test
genes were run in duplicate/run. Three separate ex-
periments were performed. LightCycler 96 settings were:
pre-incubation at 95 °C for 10 min, 3-step amplification
(45 cycles of 95 °C 10 s, 60 °C 10 s, 72 °C 10 s), melting
(95 °C 10 s, 65 °C 60 s, and 97 °C 1 s), and a final cooling
at 37 °C for 30 s. CT values [23] and standard devia-
tions were calculated and statistics were done using Z
Score values with a Bonferroni correction. With the
Bonferroni correction for 20 genes, a P <0.0025 was
considered significant.
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